What measures have EMEA governments taken in the life sciences sector to fight COVID-19?
As COVID-19 rapidly spreads to every corner of the globe and is officially declared a pandemic, governments across the world are adopting emergency measures to fight against this extraordinary situation. Ultimately, all these measures are aimed at protecting the health and well-being of citizens. However, on the healthcare and life sciences front in particular, such measures range from intervention powers to guarantee adequate supplies of treatment and medical equipment, to the relaxation of deadlines and regulatory requirements to simplify administrative procedures wherever possible, so that competent authorities, manufacturers and other actors can focus on urgent priorities related to the COVID-19 crisis.
The Baker McKenzie Healthcare and Life Sciences Industry Group is pleased to provide you with an overview of the measures that governments across the EMEA region, which includes some of the worst hit countries, have adopted in the area of healthcare and life sciences in response to the COVID-19 outbreak.
In this guide, Baker McKenzie lawyers across EMEA share their high-level views on the following areas:
Requisition powers
Price and reimbursement
Public procurement
|
Legal deadlines
Relaxation of regulatory rules
|
The full guide is now available and can be found here.